

Supporting Information for

Original article

Novel PF74-like small molecules targeting the HIV-1 capsid protein: balance of potency and metabolic stability

Lei Wang^{a,d}, Mary C. Casey^b, Sanjeev Kumar V. Vernekar^a, Rajkumar Lalji Sahani^a, Karen A. Kirby^c, Haijuan Du^c, Huanchun Zhang^c, Philip R. Tedbury^c, Jiashu Xie^a, Stefan G. Sarafianos^c, Zhengqiang Wang^{a,*}

^a*Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA*

^b*Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Christopher S. Bond Life Sciences Center, Columbia, MO 65211, USA*

^c*Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA*

^d*Department of Pharmaceutical Sciences, School of Chemical Engineering, Dalian University of Technology, Dalian 116024, China*

*Corresponding author. Tel.: +1 612 6267025.


E-mail address: wangx472@umn.edu (Zhengqiang Wang).

Received 17 June 2020; received in revised form 8 July 2020; accepted 20 July 2020


Table of contents

1. Synthesis of intermediates	S2–S6
2. NMR spectra	S7–S32
3. HR-MS spectra	S33–S45

1. Synthesis of intermediates



Reagents and conditions: (i) amine, T₃P, DIPEA, DMF, rt, 12 h; (ii) TFA; DCM, rt, 4–6 h; (iii) HATU, DIPEA, DMF, rt, 12 h.




Reagents and conditions: (i) *N*-methylaniline, T₃P, DIPEA, DMF, rt, 12 h; (ii) TFA; DCM, rt, 6 h; (iii) HATU, DIPEA, DMF, rt, 12 h.

1.1. Synthesis of **29**


To a solution of (*tert*-butoxycarbonyl)-*L*-phenylalanine (1.0 g, 1 equiv.) in DMF (5 mL), T₃P (2 equiv.) and DIPEA (3 equiv.) were added and the mixture was stirred at room temperature for 20 min before amine (1.5 equiv.) was added. The mixture was further stirred at room temperature overnight. Upon completion, H₂O was added and the reaction mixture was extracted with EtOAc (3×50 mL). The organic phases were combined and washed with brine, dried over anhydrous MgSO₄, filtered and concentrated. The product was purified by Combi-flash on silica gel using EtOAc/hexane.

1.2. Synthesis of **30**


TFA (5 equiv.) was added dropwise to a solution of **29** (1 equiv.) in DCM (5 mL) and the mixture was stirred at room temperature for 4–6 h. The solvent was evaporated to give the product as a TFA salt.




$^1\text{H NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 7.36–7.31 (m, 3H), 7.20–7.14 (m, 3H), 6.96–6.90 (m, 2H), 6.83 (d, $J = 8.2$ Hz, 2H), 3.30 (t, $J = 6.8$ Hz, 1H), 3.06 (s, 3H), 2.71 (dd, $J = 12.7$, 6.8 Hz, 1H), 2.43 (dd, $J = 13.2$, 7.8 Hz, 1H).




$^1\text{H NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ 7.20–7.12 (m, 5H), 6.86–6.80 (m, 4H), 3.33–3.30 (m, 1H), 3.02 (s, 3H), 2.71 (dd, $J = 13.1$, 7.3 Hz, 1H), 2.44 (dd, $J = 12.8$, 6.8 Hz, 1H), 2.28 (s, 3H).




$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.37–7.20 (m, 6H), 6.98–6.97 (m, 3H), 4.12–4.10 (m, 1H), 3.10 (s, 3H), 3.08–3.02 (m, 2H).




$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.37–7.21 (m, 7H), 6.98–6.97 (m, 2H), 4.15–4.12 (m, 1H), 3.12 (s, 3H), 3.10–3.03 (m, 2H).



$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.32–7.27 (m, 4H), 6.98–6.93 (m, 5H), 4.09–4.06 (m, 1H), 3.12 (s, 3H), 3.05–3.04 (m, 2H).




$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.32–7.22 (m, 5H), 7.00–6.97 (m, 4H), 4.17–4.14 (m, 1H), 3.11 (s, 3H), 3.10–3.03 (m, 2H).



$^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.31–7.23 (m, 8H), 6.97–6.96 (m, 2H), 4.03–4.00 (m, 1H), 3.76–3.72 (m, 1H), 3.48–3.43 (m, 1H), 3.08–3.01 (m, 2H), 1.00 (t, $J = 7.2$ Hz, 3H).

1.3. Synthesis of **35**

Synthesis of **35** is similar to the synthesis of **30** except (*R*)-2-((*tert*-butoxycarbonyl)amino)-2-phenylacetic acid (**33**) was used in the first step. $^1\text{H NMR}$ (600 MHz, $\text{DMSO}-d_6$) δ 8.53 (s, 3H), 7.39–7.25 (m, 6H), 6.99–6.95 (m, 2H), 6.89–6.86 (m, 2H), 4.91 (s, 1H), 3.19 (s, 3H).



Reagents and conditions: (i) L-proline methyl ester hydrochloride, T₃P, DIPEA, DMF, rt, 12 h; (ii) LiOH, MeOH/H₂O, rt, overnight; (iii) aniline, HATU, DIPEA, DMF, rt, 12 h; (iv) TFA; DCM, rt, 6 h; (v) HATU, DIPEA, DMF, rt, 12 h.

1.4. Synthesis of **37**

To a solution of (*tert*-butoxycarbonyl)-L-phenylalanine (0.5 g, 1 equiv.) in DMF (5 mL), T₃P (2 equiv.) and DIPEA (3 equiv.) were added and the mixture was stirred at room temperature for 20 min before L-proline methyl ester hydrochloride (1.5 equiv.) was added. The mixture was further stirred at room temperature overnight. Upon completion, H₂O was added and the reaction mixture was extracted with EtOAc (3×50 mL). The organic phases were combined and washed with brine, dried over anhydrous MgSO₄, filtered and concentrated. The product was purified by Combi-flash on silica gel using EtOAc/hexane.

1.5. Synthesis of **38**

Compound **37** (1 equiv.) and LiOH (3 equiv.) were dissolved in 10 mL mixture of H₂O/MeOH (2:8). The reaction mixture was stirred for overnight. Solvent was removed under vacuum and the solution was acidified to pH 2 by HCl 2N. The crude mixture was filtered to give desired product.


1.6. Synthesis of **39**


To a solution of **38** (1 equiv.) in DMF, HATU (2 equiv.) and DIPEA (3 equiv.) were added and the mixture was stirred at room temperature for 20 min before aniline (1.5 equiv.) was added. The mixture was further stirred at RT overnight. Upon completion, H₂O was added and the reaction mixture was extracted with EtOAc (3×50 mL). The organic phases were combined and washed with brine, dried over anhydrous MgSO₄, filtered and concentrated. The product was purified by Combi-flash on silica gel using EtOAc/hexane.



1.7. Synthesis of **40**



TFA (5 equiv.) was added dropwise to a solution of **39** (1 equiv.) in DCM (5 mL) and the mixture was stirred at room temperature for 6 h. The solvent was evaporated to give the product **40** as a TFA salt. ¹H NMR (600 MHz, CDCl₃) δ 9.25 (s, 1H), 7.61 (d, *J* = 7.8 Hz, 2H), 7.31–7.28 (m, 2H), 7.19–7.14 (m, 3H), 7.12–7.06 (m, 3H), 4.50–4.45 (m, 1H), 4.20–4.14 (m, 1H), 3.19 (q, *J* = 7.2 Hz, 1H), 3.06–2.95 (m, 2H), 2.71–2.63 (m, 1H), 2.07–2.04 (m, 1H), 1.90–1.82 (m, 2H), 1.80–1.71 (m, 1H).




2. NMR spectra



























































































3. HR-MS spectra

